OncoMed Pharmaceuticals, Inc. (OMED) Commences Third Phase 1b Clinical Trial For OMP-54F28 (Fzd8-Fc) With Carboplatin And Paclitaxel In Ovarian Cancer
2/20/2014 9:13:41 AM
REDWOOD CITY, Calif., Feb. 20, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced the initiation of patient treatment for its third multi-center Phase 1b clinical trial of OMP-54F28 (Fzd8-Fc) with carboplatin and paclitaxel in patients with platinum-sensitive ovarian cancer. OMP-54F28 is a first-in-class decoy receptor targeting the Wnt pathway and is part of OncoMed's collaboration with Bayer Pharma AG (Bayer).
Help employers find you! Check out all the jobs and post your resume.
comments powered by